A U.S. regulatory decision on tolebrutinib will again be delayed while a late-stage trial of the drug for a different form of ...

Sanofi will not be pursuing approval of tolebrutinib for PPMS, and an FDA decision on the therapy in nonrelapsing SPMS will ...

MS relapses are more common in spring and summer, coinciding with warmer, drier weather and atmospheric changes, a study ...

French drugmaker Sanofi on Monday flagged another delay to a U.S. regulatory decision for its experimental multiple sclerosis ...

If gut bacteria are too similar to the protective layer of nerves, they can misdirect the immune system and cause it to ...

Sanofi’s multiple sclerosis hopeful tolebrutinib faced dual setbacks on Monday, with a late-stage failure in one form of the disease and yet another regulatory setback in another.

Multiple sclerosis (MS) is a chronic autoimmune disease characterized by the disruption of nerve signals and various ...

WEDNESDAY, Dec. 17, 2025 (HealthDay News) — An over-the-counter supplement called lipoic acid might help slow the loss of ...

With a new edition of a long-running awareness campaign, Genentech is drawing attention to the talents and passions that are ...

The over-the-counter supplement lipoic acid may have a small beneficial effect in slowing the loss of gray matter in the ...

New research shows some gut bacteria mimic myelin, tricking immunity to attack nerves and worsen MS. Non-inflammatory ...

Heat sensitivity in multiple sclerosis is well known, but doctors say cold weather can also worsen symptoms. From nerve ...